Skip to main content

The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn.

Publication ,  Journal Article
Aleem, S; Robbins, C; Murphy, B; Elliott, S; Akinyemi, C; Paredes, N; Tolia, VN; Zimmerman, KO; Goldberg, RN; Benjamin, DK; Greenberg, RG
Published in: J Perinatol
April 2021

OBJECTIVE: Characterize association between hydrocortisone receipt and hospital outcomes of infants with persistent pulmonary hypertension of the newborn (PPHN). STUDY DESIGN: Cohort study of infants ≥34 weeks with PPHN who received inhaled nitric oxide at <7 days of age (2010-2016). We generated propensity scores, and performed inverse probability-weighted regression to estimate hydrocortisone effect on outcomes: death, chronic lung disease (CLD), oxygen at discharge. RESULTS: Of 2743 infants, 30% received hydrocortisone, which was associated with exposure to mechanical ventilation, sedatives, paralytics, or vasopressors (p < 0.001). There was no difference in death, CLD, or oxygen at discharge. In infants with meconium aspiration syndrome, hydrocortisone was associated with decreased oxygen at discharge (odds ratio 0.56; 95% confidence interval 0.21, 0.91). CONCLUSIONS: There was no association between hydrocortisone receipt and death, CLD, or oxygen at discharge in our cohort. Prospective studies are needed to evaluate the effectiveness of hydrocortisone in infants with PPHN.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Perinatol

DOI

EISSN

1476-5543

Publication Date

April 2021

Volume

41

Issue

4

Start / End Page

794 / 800

Location

United States

Related Subject Headings

  • Persistent Fetal Circulation Syndrome
  • Pediatrics
  • Nitric Oxide
  • Meconium Aspiration Syndrome
  • Infant, Newborn
  • Infant
  • Hypertension, Pulmonary
  • Hydrocortisone
  • Humans
  • Cohort Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aleem, S., Robbins, C., Murphy, B., Elliott, S., Akinyemi, C., Paredes, N., … Greenberg, R. G. (2021). The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn. J Perinatol, 41(4), 794–800. https://doi.org/10.1038/s41372-021-00943-9
Aleem, Samia, Cliff Robbins, Brianna Murphy, Stephen Elliott, Christiana Akinyemi, Nicholas Paredes, Veeral N. Tolia, et al. “The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn.J Perinatol 41, no. 4 (April 2021): 794–800. https://doi.org/10.1038/s41372-021-00943-9.
Aleem S, Robbins C, Murphy B, Elliott S, Akinyemi C, Paredes N, et al. The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn. J Perinatol. 2021 Apr;41(4):794–800.
Aleem, Samia, et al. “The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn.J Perinatol, vol. 41, no. 4, Apr. 2021, pp. 794–800. Pubmed, doi:10.1038/s41372-021-00943-9.
Aleem S, Robbins C, Murphy B, Elliott S, Akinyemi C, Paredes N, Tolia VN, Zimmerman KO, Goldberg RN, Benjamin DK, Greenberg RG. The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn. J Perinatol. 2021 Apr;41(4):794–800.

Published In

J Perinatol

DOI

EISSN

1476-5543

Publication Date

April 2021

Volume

41

Issue

4

Start / End Page

794 / 800

Location

United States

Related Subject Headings

  • Persistent Fetal Circulation Syndrome
  • Pediatrics
  • Nitric Oxide
  • Meconium Aspiration Syndrome
  • Infant, Newborn
  • Infant
  • Hypertension, Pulmonary
  • Hydrocortisone
  • Humans
  • Cohort Studies